title: Natalizumab in the treatment of Crohn's disease.
abstract: The pathogenesis of Crohn's disease (CD) is multifactorial and the activation of specific pathways of immunological system is important. In particular, the adhesion molecules (integrins) mediate the selective binding between the leukocytes and the endothelial cells regulating the migration of leukocytes into the normal and inflamed intestine. Selective adhesion molecule inhibitors interfere with the migration of leukocytes to the sites of inflammation by targeting adhesion molecules (alpha4-integrin or alpha4beta7-integrin). Natalizumab is a humanized IgG4 anti-alpha4-integrin monoclonal antibody that inhibits both alpha4beta7-integrin/mucosal addressin-cell adhesion molecule-1 (MadCAM-1) interaction and alpha4beta1/vascular-cell adhesion molecule-1 (VCAM-1) binding. Pooled data from the four studies, analyzed in a Cochrane review, suggest that natalizumab is effective for induction of clinical response and remission in patients with moderately to severely active CD. In particular, natalizumab may be beneficial for patients with active inflammation or chronically active disease despite the use of conventional therapies with high level of C-reactive protein values at baseline time. Nevertheless, many problems about the utilization of natalizumab in CD remain unsolved (such as the high placebo response, the final definition of dosage and timing schedule, the definition of outcomes and the development of adverse events).
authors.affiliation: Gastroenterology Unit, Department of Clinical Sciences, University of Rome "La Sapienza", Rome, Italy.
authors.forename: Danila
authors.initials: D
authors.lastname: Guagnozzi
authors.forename: Renzo
authors.initials: R
authors.lastname: Caprilli
references.citation: Gastroenterology. 1996 Nov;111(5):1373-80
references.pmid: 8898653
references.citation: J Immunol. 1997 Mar 1;158(5):2099-106
references.pmid: 9036954
references.citation: N Engl J Med. 2003 Jan 2;348(1):15-23
references.pmid: 12510038
references.citation: Aliment Pharmacol Ther. 2002 Apr;16(4):699-705
references.pmid: 11929387
references.citation: Cell. 1994 Jan 28;76(2):301-14
references.pmid: 7507411
references.citation: J Clin Invest. 1993 Jul;92(1):372-80
references.pmid: 7686922
references.citation: N Engl J Med. 2005 Jul 28;353(4):375-81
references.pmid: 15947078
references.citation: Curr Opin Gastroenterol. 2007 Jul;23(4):395-9
references.pmid: 17545775
references.citation: Nature. 1992 Mar 5;356(6364):63-6
references.pmid: 1538783
references.citation: Cell. 1995 Feb 10;80(3):413-22
references.pmid: 7532110
references.citation: Lab Invest. 2000 Oct;80(10):1541-51
references.pmid: 11045571
references.citation: N Engl J Med. 2005 Nov 3;353(18):1965-8
references.pmid: 16267329
references.citation: Genes Dev. 1995 Aug 1;9(15):1883-95
references.pmid: 7544312
references.citation: Gastroenterology. 1990 Apr;98(4):811-8
references.pmid: 2179031
references.citation: World J Gastroenterol. 2006 Aug 7;12(29):4628-35
references.pmid: 16937430
references.citation: N Engl J Med. 2000 Oct 5;343(14):1020-34
references.pmid: 11018170
references.citation: Gastroenterology. 2001 Aug;121(2):268-74
references.pmid: 11487536
references.citation: N Engl J Med. 2005 Jul 28;353(4):414-6
references.pmid: 15947082
references.citation: N Engl J Med. 2005 Jul 28;353(4):362-8
references.pmid: 15947080
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006097
references.pmid: 17253580
references.citation: N Engl J Med. 2005 Jul 28;353(4):369-74
references.pmid: 15947079
references.citation: N Engl J Med. 2006 Mar 2;354(9):924-33
references.pmid: 16510746
references.citation: N Engl J Med. 2003 Jan 2;348(1):24-32
references.pmid: 12510039
references.citation: J Cell Biol. 1995 Mar;128(6):1243-53
references.pmid: 7534768
references.citation: Cell. 2002 Sep 20;110(6):673-87
references.pmid: 12297042
references.citation: N Engl J Med. 2005 Nov 3;353(18):1912-25
references.pmid: 16267322
references.citation: Lancet. 1998 Nov 28;352(9142):1742-6
references.pmid: 9848350
references.citation: N Engl J Med. 2005 Jul 28;353(4):432-3
references.pmid: 15947083
references.citation: Gastroenterology. 2007 May;132(5):1672-83
references.pmid: 17484865
references.citation: Gastroenterology. 1998 Jul;115(1):182-205
references.pmid: 9649475
references.citation: Anticancer Res. 2005 Mar-Apr;25(2A):1079-85
references.pmid: 15868949
references.citation: FASEB J. 1995 Aug;9(11):1103-11
references.pmid: 7544310
references.citation: Science. 1996 Apr 5;272(5258):60-6
references.pmid: 8600538
references.citation: Am J Transplant. 2005 Mar;5(3):582-94
references.pmid: 15707414
references.citation: Curr Opin Gastroenterol. 2005 Jan;21(1):85-9
references.pmid: 15687890